Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 2
Author(s): Neha Mehta-Shah, Steven Horwitz
Teaser
Peripheral T-cell lymphomas represent 10% to 15% of non-Hodgkin lymphomas and comprise more than 20 different entities. Treatment of very rare T-cell lymphomas can be challenging because there are no large or randomized studies to guide clinical decision making, and treatment paradigms are often based on small series or imperfect data. Although a strict algorithm cannot be written with certainty, through the literature that exists and clinical experience, themes and principles of approaches do emerge that when coupled with clinical judgment allow reasonable and logical decisions.http://ift.tt/2nFp7v5
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου